News Sentiment

NEO sentiment intelligence

NeoGenomics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 56 Balanced news tone 43 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Diagnostics & Research Read-through group
Latest close 14.11 Week of 10 Jul 2026
Weighted tone 56/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

82/100 classification confidence.

Company focus 43

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend inactive

-6.9% over one week, +26.5% over four weeks, trend inactive, and near fair-value range.

Latest direct headline Neutral

ETFs Investing in NeoGenomics, Inc. Stocks

Market Reaction

Price moving ahead of tone

66/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 82/100 classification
One-week reaction -6.9% Price reacting lower
Trend fit Trend inactive 26.5% over four weeks
Fair value 12.4% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 13
Neutral 28
Negative 2

Relevance

Why the article matched

Direct first
Direct company coverage 43
Industry context 0
Sector context 0

Sources

Coverage mix

Publishers
TradingView 12
Stock Titan 7
simplywall.st 5
Market source 4
Simply Wall Street 2
StockStory 2
Business Wire 2
The Globe and Mail 1

Event Lens

What the news is about

Classified themes
Market update 27
Earnings 11
Analyst action 4
Balance sheet 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 43
TradingView Direct company coverage

ETFs Investing in NeoGenomics, Inc. Stocks

This article lists various Exchange Traded Funds (ETFs) that hold NeoGenomics, Inc. (NG9) stocks, sorted by market value. It provides detailed financial information for each ETF, including weight in the fund, issuer, management style, focus, expense ratio, assets under management

Tone
Neutral 50/100
Event
Market update
Published
14 Jul 2026 13:41
Source
TradingView
The Globe and Mail Direct company coverage

Bank of America Securities Reaffirms Their Hold Rating on NeoGenomics (NEO)

Bank of America Securities analyst Michael Ryskin has maintained a Hold rating on NeoGenomics (NEO) with a price target of $16.00. The company's latest earnings report showed increased quarterly revenue but a continued GAAP net loss. Analyst consensus for NeoGenomics is a Moderat

Tone
Neutral 50/100
Event
Analyst action
Published
14 Jul 2026 10:41
Source
The Globe and Mail
Simply Wall Street Direct company coverage

Does NeoGenomics (NEO) New PTEN CDx Move Reveal a Deeper Precision Oncology Strategy Shift?

NeoGenomics recently launched PTEN IHC CDx, the first FDA-approved companion diagnostic for prostate adenocarcinoma, which helps identify patients eligible for AstraZeneca's TRUQAP. This development expands NeoGenomics' presence in urologic oncology and personalized prostate canc

Tone
Neutral 50/100
Event
Market update
Published
14 Jul 2026 06:41
Source
Simply Wall Street
Investing.com Direct company coverage

NeoGenomics launches FDA-approved prostate cancer diagnostic test

NeoGenomics has launched PTEN IHC CDx, an FDA-approved companion diagnostic test for prostate cancer. This test identifies PTEN protein loss in patients who may benefit from AstraZeneca's TRUQAP therapy. The company has seen significant stock growth and is predicted to be profita

Tone
Positive 74/100
Event
Market update
Published
09 Jul 2026 11:40
Source
Investing.com
Business Wire Direct company coverage

NeoGenomics Launches FDA-Approved PTEN IHC Companion Diagnostic for Prostate Cancer

NeoGenomics, Inc. has launched PTEN IHC CDx, the first FDA-approved immunohistochemistry companion diagnostic for prostate adenocarcinoma patients. This test identifies PTEN protein loss, making patients eligible for AstraZeneca's TRUQAP® therapy. It is available as a standalone

Tone
Positive 71/100
Event
Market update
Published
09 Jul 2026 10:40
Source
Business Wire
Stock Traders Daily Direct company coverage

(NEO) Volatility Zones as Tactical Triggers

This article from Stock Traders Daily discusses Neogenomics Inc. (NYSE: NEO), highlighting weak near-term sentiment but compelling upside potential without resistance levels above the current price. It outlines three AI-generated trading strategies—Position Trading, Momentum Brea

Tone
Neutral 50/100
Event
Market update
Published
08 Jul 2026 23:54
Source
Stock Traders Daily
AD HOC NEWS Direct company coverage

NeoGenomics Inc focuses on diagnostics growth as investors watch long-term margins

NeoGenomics Inc is a specialized diagnostics company focusing on cancer testing services, including routine pathology and advanced molecular assays. The company supports physicians, hospitals, and biopharmaceutical firms, offering services critical for treatment decisions and cli

Tone
Neutral 50/100
Event
Market update
Published
07 Jul 2026 16:13
Source
AD HOC NEWS
BioSpace Direct company coverage

NeoGenomics to Report Second Quarter 2026 Financial Results on July 28, 2026

NeoGenomics, Inc. announced it will release its second quarter 2026 financial results after the close of U.S. financial markets on Tuesday, July 28, 2026. The company will host a webcast and conference call at 4:30 p.m. ET to discuss the results and recent highlights. Interested

Tone
Neutral 50/100
Event
Earnings
Published
07 Jul 2026 12:39
Source
BioSpace
Investing.com India Direct company coverage

Neogenomics stock hits 52-week high at 15.56 USD By Investing.com

NeoGenomics Inc. stock recently hit a 52-week high of $15.56, indicating strong investor confidence with a 100.79% total return according to InvestingPro data. The company has also been active with financial maneuvers, including pricing $275 million in convertible senior notes, a

Tone
Positive 75/100
Event
Market update
Published
06 Jul 2026 21:10
Source
Investing.com India
Moomoo Direct company coverage

NeoGenomics on Track for Longest Winning Streak Since February 2019 -- Data Talk

NeoGenomics (NEO) is experiencing its longest winning streak since February 2019. The company's stock has seen five consecutive days of gains. In the last year, NeoGenomics has outperformed the S&P 500, marking a positive trend for investors.

Tone
Neutral 50/100
Event
Market update
Published
06 Jul 2026 18:13
Source
Moomoo
Finviz Direct company coverage

NEO - Neogenomics Inc Latest SEC Filings

This article provides the latest SEC filings information for Neogenomics Inc (NEO), along with a detailed overview of its financial data, stock performance metrics, and key ratios. It includes market capitalization, income, sales, EPS, insider ownership, institutional ownership,

Tone
Neutral 50/100
Event
Earnings
Published
06 Jul 2026 06:10
Source
Finviz
Simply Wall Street Direct company coverage

Is NeoGenomics (NEO) Quietly Reframing Its Oncology Data Strategy With Starrett’s Board Appointment?

NeoGenomics (NEO) has appointed Carolyn Starrett, a former Flatiron Health CEO known for her expertise in AI and healthcare data, to its Board of Directors. This move, combined with its Epic Aura integration, suggests NeoGenomics is enhancing its oncology data strategy to differe

Tone
Positive 64/100
Event
Market update
Published
02 Jul 2026 17:39
Source
Simply Wall Street
TradingView Direct company coverage

Price to earnings forward of NeoGenomics, Inc. – NASDAQ:NEO

This page from TradingView displays the "Price to earnings forward" metric for NeoGenomics, Inc. (NASDAQ: NEO). It indicates that the specific financial value for this metric is not provided directly on this overview page, showing only "Period", "Value", and "Change %" fields whi

Tone
Neutral 50/100
Event
Earnings
Published
29 Jun 2026 08:09
Source
TradingView
TradingView Direct company coverage

Enterprise value to EBIT forward of NeoGenomics, Inc. – NASDAQ:NEO

This article focuses on the enterprise value to EBIT forward metric for NeoGenomics, Inc. (NASDAQ: NEO). It presents financial data and analysis specific to this valuation ratio. The article is hosted on TradingView, a financial platform offering various market tools and data.

Tone
Neutral 50/100
Event
Market update
Published
27 Jun 2026 17:09
Source
TradingView
TradingView Direct company coverage

NeoGenomics, Inc. Actuals & Estimates (NASDAQ:NEO)

This article provides an overview of NeoGenomics, Inc. (NASDAQ: NEO) stock, covering its current price, market capitalization, historical performance, and analyst forecasts. It also details the company's recent financial results, including earnings, revenue, and net income, along

Tone
Positive 70/100
Event
Earnings
Published
27 Jun 2026 16:10
Source
TradingView
TradingView Direct company coverage

Enterprise value to EBITDA forward of NeoGenomics, Inc. – NASDAQ:NEO

This article provides financial information for NeoGenomics, Inc. under the NASDAQ ticker NEO, specifically focusing on its enterprise value to EBITDA forward. It indicates basic financial data for the company is available through TradingView.

Tone
Neutral 50/100
Event
Market update
Published
27 Jun 2026 16:10
Source
TradingView
TradingView Direct company coverage

Price to sales forward of NeoGenomics, Inc. – NASDAQ:NEO

This page provides financial data for NeoGenomics, Inc. (NASDAQ: NEO), specifically its price to sales forward metric. The content highlights the company's financials, news, and other relevant market information on TradingView. It appears to be a stub or a data-only content piece

Tone
Neutral 50/100
Event
Market update
Published
27 Jun 2026 11:40
Source
TradingView
TradingView Direct company coverage

Enterprise value to revenue forward of NeoGenomics, Inc. – NASDAQ:NEO

This article focuses on the enterprise value to revenue forward metric for NeoGenomics, Inc. (NASDAQ: NEO). It presents financial data for the company under the NASDAQ stock market. The content primarily consists of navigational elements and data sourcing information, with the co

Tone
Neutral 50/100
Event
Earnings
Published
27 Jun 2026 04:09
Source
TradingView
TradingView Direct company coverage

NEO Forecast — Price Target — Prediction for 2027

This article provides a forecast and price target for NeoGenomics, Inc. (NEO), based on analyst ratings and future predictions for 2027. It details the company's current stock performance, market capitalization, volatility, and addresses frequently asked questions regarding its f

Tone
Positive 72/100
Event
Analyst action
Published
27 Jun 2026 02:10
Source
TradingView
Gulfshore Business Direct company coverage

Carolyn Starrett joins NeoGenomics board of directors team

NeoGenomics Inc. has appointed Carolyn Starrett to its board of directors. This announcement is part of a broader update on new hires and leadership appointments within various SWFL businesses. Other organizations like Collaboratory, Priority Marketing, and Capital Wealth Advisor

Tone
Positive 57/100
Event
Market update
Published
26 Jun 2026 17:39
Source
Gulfshore Business
Stock Titan Direct company coverage

NeoGenomics (NASDAQ: NEO) director receives new RSU and stock option grants

NeoGenomics director Carolyn S. Starrett was granted 14,125 Restricted Stock Units and stock options for 9,784 shares of common stock on June 23, 2026. The stock options have an exercise price of $11.20 per share and expire on June 1, 2036. These equity awards are compensation gr

Tone
Neutral 50/100
Event
Market update
Published
26 Jun 2026 17:10
Source
Stock Titan
TradingView Direct company coverage

NeoGenomics, Inc. Actuals & Estimates (FWB:NG9)

This article provides an overview of NeoGenomics, Inc. (FWB:NG9) financial data and analyst estimates, including income statement, balance sheet, and cash flow information. It details stock performance, analyst price targets, and key financial metrics like earnings per share, rev

Tone
Positive 65/100
Event
Earnings
Published
26 Jun 2026 13:40
Source
TradingView
TradingView Direct company coverage

NeoGenomics, Inc. Actuals & Estimates (DUS:NG9)

This article provides financial actuals and estimates for NeoGenomics, Inc. (NG9) on the Dusseldorf Stock Exchange. It covers income statement, balance sheet, cash flow, and valuation metrics, along with analyst price targets. Key information includes a max price estimate of 21.2

Tone
Neutral 50/100
Event
Analyst action
Published
26 Jun 2026 08:39
Source
TradingView
Stock Titan Direct company coverage

NeoGenomics (NEO) director Carolyn Starrett files initial Form 3

NeoGenomics (NEO) director Carolyn Starrett has filed an initial Form 3 with the SEC, indicating her new status as a reporting insider for the company. The filing shows no transactions or holdings at this time, serving as an initial disclosure of beneficial ownership. This transp

Tone
Neutral 50/100
Event
Market update
Published
26 Jun 2026 07:10
Source
Stock Titan
TradingView Direct company coverage

A Look Back at Testing & Diagnostics Services Stocks’ Q1 Earnings: NeoGenomics (NASDAQ:NEO) Vs The Rest Of The Pack

This article reviews the Q1 earnings of several testing and diagnostics services stocks, highlighting NeoGenomics (NEO), Guardant Health (GH), RadNet (RDNT), Labcorp (LH), and Quest Diagnostics (DGX). It notes that the industry as a whole reported strong Q1 results, with revenues

Tone
Positive 73/100
Event
Earnings
Published
26 Jun 2026 03:39
Source
TradingView